DelayedPDUFA target action date

Mitapivat

Agios Pharmaceuticals (AGIO)

Marketer take

Date moved from Nov 1, 2026 while FDA weighs whether a REMS is needed, which could shape how the brand is marketed and dispensed.

Sponsor company
Agios Pharmaceuticals (AGIO)
Indication
Sickle cell disease (accelerated approval sNDA)
Therapeutic area
Hematology
Event
PDUFA target action date
Date
Feb 1, 2027
Previous date
Nov 1, 2026 (moved)
Status
Delayed
Source
SEC filing
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move